Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study
Clinical and Experimental Dermatology · 24.02.2026 · 51 (3) · 442-450
DOI: 10.1093/ced/llaf473 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 25.10.2025. Verfasst von Joana Nicolau und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic …. Hauptthemen laut MEDLINE: Psoriasis, Obesity, Glucagon-Like Peptides. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Psoriasis is a chronic inflammatory skin disease often associated with obesity and metabolic dysfunction, which may worsen disease severity. Glucagon-like peptide-1 receptor agonists, such as semaglutide, have shown metabolic and anti-inflammatory effects, but their impact on psoriasis in patients with obesity and without diabetes remains unclear.
Objectives
To evaluate the effects of a 6-month semaglutide treatment on psoriasis severity and clinical, metabolic, inflammatory and psychosocial parameters in patients with psoriasis and obesity.
Methods
In this prospective cohort study, 43 patients received weekly semaglutide along with lifestyle counselling. Psoriasis severity (Psoriasis Area and Severity Index, PASI), quality of life (Dermatology Life Quality Index, DLQI), depressive symptoms (Beck Depression Inventory, BDI), nutritional ultrasound and biochemical markers were assessed at baseline and after 6 months. Correlations between PASI improvement (ΔPASI) and baseline variables and their changes were analysed, adjusting for age and weight loss.
Results
After 6 months, participants showed significant reductions in PASI (–48%), body mass index (BMI), preperitoneal and superficial fat, along with improvements in DLQI, BDI and metabolic markers. Baseline disease severity, depressive symptoms, insulin resistance and preperitoneal fat were negatively associated with PASI improvement. These associations remained significant after adjustment [e.g. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), r = –0.82; preperitoneal fat, r = –0.66]. ΔPASI was most strongly correlated with reductions in superficial fat (r = 0.89), DLQI (r = 0.55) and BDI (r = 0.51). Changes in BMI and glycaemic markers were not significantly associated after adjustment.
Conclusions
In patients with psoriasis and obesity, semaglutide improves both skin disease and systemic health. The clinical benefit appears associated with specific fat loss and psychosocial improvement, beyond overall weight reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
- Interdisciplinary Group in Neurodegeneration, Vascular and Metabolic Diseases, University of Balearic Islands (UIB), Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
- Dermatology Department. Son Llàtzer University Hospital, Palma de Mallorca, Spain.
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, 28029 Madrid, Spain.
ORCID-Profile: Joana Nicolau
Zitieren
APA
Nicolau, J., Nadal, A., Sanchís, P., Pujol, A., Tamayo, M. I., Sfondrini, G., Grimalt, M., García, P., Nadal, C., & Masmiquel, L. (2026). Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study. Clinical and Experimental Dermatology, 51(3), 442-450. https://doi.org/10.1093/ced/llaf473
Vancouver
Nicolau J, Nadal A, Sanchís P, Pujol A, Tamayo MI, Sfondrini G, et al. Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study. Clinical and Experimental Dermatology. 2026;51(3):442-450. doi:10.1093/ced/llaf473
BibTeX
@article{Nicolau2026,
author = {Nicolau, Joana and Nadal, Antoni and Sanchís, Pilar and Pujol, Antelm and Tamayo, María Isabel and Sfondrini, Guido and Grimalt, Mireia and García, Paula and Nadal, Cristina and Masmiquel, Lluís},
title = {Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study},
journal = {Clinical and Experimental Dermatology},
year = {2026},
volume = {51},
number = {3},
pages = {442--450},
doi = {10.1093/ced/llaf473}
}
EUVIMED